Working… Menu
Trial record 18 of 857 for:    ALBUTEROL

Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED) (Xopenex)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00585039
Recruitment Status : Completed
First Posted : January 2, 2008
Results First Posted : August 16, 2011
Last Update Posted : September 9, 2011
Information provided by:
Phoenix Children's Hospital

Brief Summary:
The purpose of this study is to determine in a large, double-blind, randomized, prospective pediatric clinical trial whether the use of continuous levalbuterol (Xopenex) in addition to standard emergency department treatment for acute asthma exacerbations will improve the Forced Expiratory Volume in 1 sec (FEV 1) compared to the use of continuous racemic albuterol. The secondary objective is to correlate clinical (hospitalization rates and clinical asthma scores) with plasma levels of (S)-albuterol.

Condition or disease Intervention/treatment Phase
Asthma Drug: xopenex Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 101 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Hospital Admission Rates and Plasma(s)-Albuterol Levels in Children Treated With Racemic Albuterol Versus Levalbuterol for Acute Asthma Exacerbations: A Randomized Double-Blind Clinical Trial
Study Start Date : September 2005
Actual Primary Completion Date : March 2009
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: A
levalbuterol nebulization
Drug: xopenex
will receive xopenex rather than albuterol to treat acute exacerbation
Other Name: levalbuterol

Primary Outcome Measures :
  1. Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec [ Time Frame: Baseline and 4 hours ]

Secondary Outcome Measures :
  1. Clinical Asthma Score (CAS) [ Time Frame: 4 hours ]
    Change in clinical asthma score while in ED. 15 point clinical asthma score. Score ranges from 5 (no to mild respiratory distress) to a maximum of 15 (severe respiratory distress).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is between the ages of 6 and 17
  • Has previously been diagnosed with asthma by any physician
  • Has presented to the ED with an asthma exacerbation judged by a physician to be of a moderate or severe degree

Exclusion Criteria:

  • Requires immediate resuscitation (attending physician)
  • Is pregnant and/or breast feeding
  • If possibly pregnant, negative pregnancy test attached
  • Has chronic lung diseases (i.e. cystic fibrosis)
  • Has an uncorrected congenital heart diseaseHas a suspected foreign body aspiration
  • Is allergic to albuterol and/or levalbuterol (Xopenex)
  • Has an initial FEV 1>70% predicted

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00585039

Layout table for location information
United States, Arizona
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85016
Sponsors and Collaborators
Phoenix Children's Hospital
Layout table for investigator information
Principal Investigator: Robert Bulloch, MD Phoenix Children's Hospital

Layout table for additonal information
Responsible Party: Robert Bulloch, MD, Phoenix Children's Hospital Identifier: NCT00585039     History of Changes
Other Study ID Numbers: SRC176
First Posted: January 2, 2008    Key Record Dates
Results First Posted: August 16, 2011
Last Update Posted: September 9, 2011
Last Verified: September 2011
Keywords provided by Phoenix Children's Hospital:
emergency department
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action